- Primary research
- Open Access
Pepsin promotes IL-8 signaling-induced epithelial–mesenchymal transition in laryngeal carcinoma
Cancer Cell International volume 19, Article number: 64 (2019)
Laryngopharyngeal reflux (LPR), with its increasing morbidity, is attracting considerable attention. In recent years, the causal role between LPR and laryngeal carcinoma has been debated. The main harmful component of LPR is pepsin, which has been shown to induce mucosal inflammation by damaging the mucous membrane. Thus, pepsin is linked to an increased risk of laryngeal carcinoma, although the potential mechanism remains largely unknown.
The human laryngeal carcinoma cell lines Hep-2 and Tu212 were exposed to different pepsin concentrations and the morphology, proliferation, migration, secretion of inflammatory cytokines, and epithelial–mesenchymal transition (EMT) of the cells were assessed. To evaluate whether interleukin-8 (IL-8) had a causal relationship with pepsin and EMT, an IL-8 inhibitor was used to suppress IL-8 secretion during pepsin exposure and the expression of EMT markers, cell proliferation, and migration were analyzed.
Pepsin promoted proliferation, colony formation, migration, and IL-8 secretion of Hep-2 and Tu212 cells in vitro. Furthermore, increased pepsin concentrations changed the morphology of Hep-2 and Tu212 cells; levels of the epithelial marker E-cadherin were reduced and those of mesenchymal markers vimentin and β-catenin and the transcription factors snail and slug were elevated. A similar effect was observed in laryngeal carcinoma tissues using immunohistochemistry. IL-8 level was reduced and EMT was restored when pepsin was inhibited by pepstatin. EMT was weakened after exposure to the IL-8 inhibitor, with significant reduction in pepsin-induced cell proliferation and migration.
Pepsin may induce EMT in laryngeal carcinoma through the IL-8 signaling pathway, which indicates that it has potential role in enhancing cell proliferation and metastasis of laryngeal carcinoma.
Laryngopharyngeal reflux (LPR) is the retrograde flow of gastric contents into the upper aerodigestive tract, which causes a variety of signs and symptoms in the throat . Extensive research has shown that LPR is closely related to chronic throat inflammation , development of vocal cord polyps , and other benign diseases. Recently, LPR has attracted increasing attention as a risk factor for laryngeal cancer.
As it is a common malignant otorhinolaryngologic tumor, laryngeal carcinoma is considered to be closely related to smoking and drinking . However, in Western countries, controlling behaviors associated with these risk factors has not significantly lowered the incidence of laryngeal carcinoma, suggesting the existence of other causes [5, 6]. Certain recent studies have supported the hypothesis that LPR is an independent risk factor in the development of laryngeal cancer [7, 8]. However, other studies support the opposite view [9, 10]. Whether LPR plays a key role in laryngeal cancer development is still controversial, partially because LPR diagnosis currently lacks a unified standard [11,12,13], which renders demonstration of the correlations between reflux and laryngeal cancer difficult.
In gastroesophageal reflux disease, acid damages the esophageal epithelium. In LPR, reflux is dominated by weak acidic reflux in both upright and supine positions ; however, nonacid refluxes, such as those of pepsin and bile acid, require further consideration. Pepsin, the main harmful component of LPR, normally exists only in the stomach, but numerous recent studies have reported it in the trachea, lung tissue, nasal mucosa, middle ear secretions, and saliva of a reflux patient [15,16,17,18]. It is widely accepted that pepsin can act as a molecular marker of reflux [19, 20]. However, only few studies have shown that pepsin in LPR contributes to the development of laryngopharyngeal carcinogenesis [21, 22], although the relevant molecular mechanism is largely unknown.
Recent studies [23, 24] have shown reflux to be associated with epithelial–mesenchymal transition (EMT). However, the contributions of LPR to laryngeal carcinoma carcinogenesis via EMT have not yet been characterized. Considering that LPR includes pepsin-containing fluids, we recently observed that pepsin expression in laryngeal tissue increases in patients with laryngeal carcinoma . In the present study, we attempted to determine whether pepsin induced laryngeal carcinoma via EMT and whether it facilitated the malignant development of laryngeal cancer.
Materials and methods
Tissue specimens and cell culture
This study was performed in accordance with institutional ethical guidelines and was approved by the Ethics Committee of the Nanfang Hospital. Informed written consent was obtained from each patient. Specimens from 87 patients with laryngeal carcinoma (two women and 85 men, aged 40 to 86 years) were collected from the laryngeal carcinoma tissue bank of the Nanfang Hospital. The tissue specimens were routinely frozen in liquid nitrogen, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned according to routine procedures.
The American Type Culture Collection (ATCC) human laryngeal carcinoma cell line Tu212 was purchased from Guangzhou Juyan Biological Technology (Guangzhou, China) and Hep-2 was purchased from Shanghai Aolu Biological Technology (Shanghai, China). The cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin/streptomycin. The cells were maintained at 37 °C in a humidified 5% CO2 atmosphere. Porcine pepsin (Sigma-Aldrich, St Louis, MO, USA) was used for pepsin exposure. The pepsin inhibitor pepstatin A and the interleukin-8 (IL-8) inhibitor SB225002 were synthetized by Selleckchem (Shanghai, China).
5-ethynyl-2′-deoxyuridine (EdU) proliferation assay
Hep-2 and Tu212 cells were seeded in 96-well plates (4 × 104/well) and exposed to different concentrations of pepsin (0 mg/ml, 0.1 mg/ml, or 1 mg/ml) at pH 7 for 2 h. The working concentration of pepsin (0.1 mg/ml and 1 mg/ml) has been used previously [21, 22, 26,27,28]. After exposure to pepsin, the cells were cultured in complete RPMI-1640 medium for 24 h and cell proliferation was detected using an EdU kit (RiboBio, Guangzhou, China) according to the manufacturer’s instructions. Images were analyzed using digital microscopy and the cells were counted using Image J software.
Hep-2 and Tu212 cells were seeded in 6-well plates and exposed to 0 mg/ml, 0.1 mg/ml, or 1 mg/ml pepsin at pH 7 twice a week for 2 h for 18 days. The cells were maintained in complete RPMI-1640 medium when not being treated with pepsin. Colonies containing > 50 cells were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet.
Cell cycle experiment
Hep-2 and Tu212 cells were inoculated in 6-cm dishes. The cultures were divided into three groups and treated with culture media containing different concentrations of pepsin as described above. Cell-cycle distribution was analyzed using propidium iodide staining (Keygentec, Nanjing, China) and flow cytometry (Becton–Dickinson, San Jose, CA, USA).
Transwell migration assay
Hep-2 and Tu212 cells suspended in 100 µl serum-free medium were seeded into the upper chambers of each insert (24-well insert; pore size, 8 μm; Corning, Corning, NY, USA) and 600 μl medium containing 10% fetal bovine serum (FBS) was added to the lower chamber. After 12 h, the medium in the lower chamber was replaced with 10% FBS and different concentrations of pepsin and incubated for 2 h. After 24 h, the cells under the bottom membrane were stained with crystal violet. The migrating cells in five randomly selected fields at a magnification of 200× were imaged using digital microscopy and counted.
Cytometric bead array (CBA)
Hep-2 and Tu212 cells were seeded into 6-well plates and exposed to different concentrations of pepsin at pH 7 for 2 h. The concentrations of cytokines IL-8, IL-6, IL-10, IL-1β, IL-12p70, and tumor necrosis factor (TNF) in the serum were measured using a Becton–Dickinson CBA software following a standard protocol. The data from the standards and experimental samples were analyzed using an LSR Fortessa flow cytometer (Becton–Dickinson) and FCAP Array software.
Extraction of total RNA and quantitative reverse transcription PCR (qRT-PCR)
Hep-2 and Tu212 cells were inoculated into 6-cm dishes and exposed to different concentrations of pepsin in the culture medium. The cells were continuously stimulated for 2 h each day for 5 days. Total RNA was extracted from the cells using RNAiso Plus (Takara, Shiga, Japan) and reverse transcribed into complementary DNA (cDNA) using an All-in-One first-strand cDNA synthesis kit (GeneCopoeia Inc., USA). The SYBR green method (GeneCopoeia Inc) was used for PCR amplification. Relative quantification using the 2−∆∆Ct method was used to determine the mRNA expression levels of EMT epithelial marker E-cadherin and mesenchymal markers vimentin and β-catenin. The housekeeping gene β-actin was used as an internal control. The primers included GAPDH forward (5′-AAGAAGGTGGTGAAGCAGGC-3′) and reverse (5′-TCCACCACCCAGTTGCTGTA-3′), E-cadherin forward (5′-CCCGGGACAACGTTTATTAC-3′) and reverse (5′-GCTGGCTCAAGTCAAAGTCC-3′), vimentin forward (5′-TGCTTCAGAGAGAGGAAGCCGAA-3′) and reverse (5′-ACGTGCCAGAGACGCATTGTCA-3′), and β-catenin forward (5′-GACCAGCTCTCTCTTCAGAACAGA-3′) and reverse (5′-GTTCTCCCTGGGCACCAATA-3′).
Western blot analysis
Hep-2 and Tu212 cells were inoculated into 6-cm dishes and exposed to different concentrations of pepsin in the culture medium. The cells were stimulated continuously for 2 h each day for 5 days. Total protein was extracted from the cells and the samples were separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). The membranes were incubated overnight with rabbit monoclonal antibodies against human E-cadherin (1:1000; Cell Signaling Technology, USA), vimentin (1:100; Cell Signaling Technology), β-catenin (1:100; Cell Signaling Technology), snail (Cell Signaling Technology), and slug (Cell Signaling Technology) transcription factors and detected using chemiluminescence. An antibody specific for β-actin (1:10,000; Kangcheng Inc, Shanghai, China) was used as an internal control.
Hep-2 and Tu212 cells were inoculated in 6-well dishes and exposed to different concentrations of pepsin in culture medium. The cells were continuously stimulated for 2 h each day for 5 days, fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.2% Triton X-100 for 10 min, blocked for 1 h with goat serum, and incubated at 4 °C overnight with primary antibodies against E-cadherin and vimentin. The nuclei of the cells in the confocal dishes were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and imaged using an inverted microscope.
Paraffin-embedded tumor specimens from patients with laryngeal carcinoma were sectioned (4 μm) and incubated with primary antibodies against pepsin, E-cadherin, vimentin, β-catenin, and IL-8 (Cell Abcam, USA). Staining was repeated at least twice in sequential sections from the same tissue blocks and the stained sections were reviewed and classified by two pathologists. The proportion of positive cells per specimen was evaluated quantitatively and scored as follows : ≤ 1% stained cells, 0; 2–25%, 1; 26–50%, 2; 51–75%, 3; and > 75%, 4. Staining intensity was scored as follows: no staining, 0; weak, 1; moderate, 2; and strong, 3. The total score (0–12) was calculated by multiplying the score of stained cells by the score of staining intensity, and was graded as negative (−; score: 0–1), weak (+; 2–4), moderate (++; 5–8), and strong (+++; 9–12).
The SPSS 19.0 software was used for statistical analysis. Analysis of variance was performed to compare data from the EdU assays, clone formation experiments, cell cycle experiments, cell migration assays, CBA assays, and qPCR analysis. Wound scratch assays were analyzed with a factorial design analysis of variance. Expression levels of pepsin, IL-8, E-cadherin, vimentin, and β-catenin in the laryngeal carcinoma specimens as determined by immunohistochemistry were compared using Spearman correlation analysis. P-values < 0.05 were considered statistically significant.
Pepsin promoted proliferation and the migratory capacity of laryngeal squamous cell carcinoma cells in vitro
The EdU assays showed that cell proliferation increased by 1.55- and 1.92-fold, and by 1.28- and 1.49-fold when the Hep-2 and Tu212 cells were treated with 0.1 mg/ml and 1 mg/ml pepsin, respectively, compared to that of cells not treated with pepsin, (P = 0.025 and P = 0.043; Fig. 1a). Similar results indicated that 0.1 mg/ml and 1 mg/ml pepsin increased the colony formation ability by 2.3- and 4.3-fold, and by 2.3- and 2.9-fold, respectively, compared to that of cells not treated with pepsin (P = 0.006 and P = 0.003; Fig. 1b). Furthermore, cell cycle distribution showed that the percentage of cells in the S-phase increased concurrently with increasing pepsin concentrations (P = 0.002 and P = 0.003; Fig. 1c).
Next, we investigated the cellular migration-inducing ability of pepsin. Transwell migration arrays revealed dramatic increases in cell motility, with 1.47- and 2.63-fold, and 2.35- and 4.40-fold increase for cells treated with 0.1 mg/ml and 1 mg/ml pepsin, respectively, compared to that of untreated Hep-2 and Tu212 cells (P < 0.001; Fig. 1d).
Pepsin altered cytokine production by laryngeal squamous cell carcinoma cells in vitro and in laryngeal carcinoma tissues
To determine whether pepsin was able to alter the expression of inflammatory cytokines, which may contribute to epithelial damage, we investigated cytokine production following stimulation with pepsin. Results demonstrated that IL-8 levels increased by 1.78- and 2.92-fold, and by 1.43- and 2.67-fold with 0.1 mg/ml and 1 mg/ml pepsin, respectively (P = 0.02 and P = 0.02). There was also a trend toward elevation of IL-6 levels by pepsin, although the observed differences did not reach statistical significance (Fig. 2a). Levels of IL-10, IL-1β, IL-12p70, and TNF showed no significant difference between cells treated or not treated with pepsin (Additional file 1: Table S1). To confirm if pepsin is involved IL-8 and IL-6 secretion in laryngeal carcinoma cells, pepsin was inhibited by pepstatin, an inhibitor of aspartate (acid) proteases, including pepsin, cathepsin D, and chymosin. IL-8 level decreased significantly by 31.4% and 34.92% (P = 0.027 and P = 0.007) and that of IL-6 decreased by 8.71% and 25.7% (P = 0.072 and P = 0.212) when pepsin was inhibited by pepstatin in Hep-2 and Tu212 cells, respectively (Fig. 2b). IL-8 may be more sensitive to pepsin than IL-6. Levels of IL-10, IL-1β, IL-12p70, and TNF were not significantly affected by pepstatin (Additional file 1: Table S2).
Furthermore, IL-8 expression was analyzed using laryngeal carcinoma specimens and immunohistochemistry. A significantly positive correlation was observed between pepsin treatment and the expression of IL-8 in laryngeal carcinoma tissue (r = 0.245, P = 0.022; Fig. 2c).
Pepsin affected laryngeal squamous cell carcinoma cell morphology and EMT induction
A dramatic morphological change was observed in Hep-2 and Tu212 cells following pepsin stimulation. The typical cobblestone-like appearance of the squamous epithelium was replaced with a spindle-like fibroblastic morphology. After stimulation with 0.1 mg/ml pepsin for 5 days, the cells demonstrated fusiform growth and an obvious spindle-shaped morphology following stimulation with 1 mg/ml pepsin (Fig. 3a).
This phenomenon suggested that Hep-2 and Tu212 cell lines exposed to pepsin may undergo EMT. Further investigation revealed that the levels of E-cadherin in Hep-2 and Tu212 cells exposed to 0.1 mg/ml and 1 mg/ml pepsin decreased by 55.50% and 30.20%, (P = 0.034), and 95.33% and 55.00% (P = 0.037), respectively, compared to that of cells not treated with pepsin. In contrast, for Hep-2 and Tu212 cells exposed to 0.1 mg/ml and 1 mg/ml pepsin, the mRNA levels of vimentin increased by 1.18- and 1.66-fold (P = 0.036), and by 1.74- and 4.28-fold (P = 0.016), respectively. The mRNA levels of β-catenin in these two cell lines increased by 1.27- and 1.58-fold (P = 0.233), and by 1.69- and 3.07-fold (P = 0.046), respectively (Fig. 3b). Western blotting and immunofluorescence analyses of Hep-2 and Tu212 cells indicated that E-cadherin expression decreased and vimentin expression increased following exposure to different concentrations of pepsin (Fig. 3c, d). Furthermore, western blot analysis showed that β-catenin, snail, and slug were upregulated with increasing concentrations of pepsin. Treatment of Hep-2 and Tu212 cells with pepsin and its inhibitor pepstatin markedly increased E-cadherin expression but reduced vimentin and β-catenin expression compared to that of cells only exposed to pepsin (Fig. 3e).
Among 87 patients with laryngeal carcinoma, immunohistochemical staining for pepsin in the tissues was strongly positive in 11 patients (12.64%), moderately positive in 26 patients (29.89%), weakly positive in 28 patients (32.18%), and negative in 22 patients (25.29%). Furthermore, as shown in Fig. 3f, pepsin expression was associated with vimentin expression (r = 0.260, P = 0.015) and β-catenin expression (r = 0.231, P = 0.032), but inversely associated with E-cadherin expression (r = − 0.262, P = 0.014).
Role of the IL-8/IL-8R axis in EMT and the proliferative and migratory capacities of laryngeal squamous cell carcinoma cell exposed to pepsin
To provide insight into the mechanism via which cytokine signals regulate pepsin-induced EMT in laryngeal carcinoma cells, SB225002 was added to the culture medium to block the IL-8 receptor CXCR2 . Treatment of the Hep-2 and Tu212 cells exposed to pepsin with SB225002 markedly increased E-cadherin expression but reduced vimentin and β-catenin expression compared to that of cells not treated with the IL-8 inhibitor. Blocking of the IL-8 receptors with SB225002 did not affect slug expression, but markedly reduced snail expression (Fig. 4a).
Next, we assessed the effect of IL-8 on the proliferation capacity of Hep-2 and Tu212 cells using EdU assays and cell cycle experiments. Blocking of the IL-8 receptors in pepsin-treated Hep-2 and Tu212 cells significantly inhibited the proliferation capacity of the cells by 66.14% and 82.35% (P = 0.001 and P = 0.017), and reduced the percentage of cells in S-phase by 86.64% and 92.94% (P = 0.025 and P = 0.000) compared to that of cells not treated with the CXCR2 inhibitor (Fig. 4b, c). Transwell migration assays revealed that blockage of the IL-8 receptor CXCR2 reduced the migratory capacities of pepsin-treated Hep-2 and Tu212 cells by 72.06% and 75.38% (P = 0.018 and P = 0.002) compared to that of cells not treated with the CXCR2 inhibitor (Fig. 4d).
Pepsin can inhibit protective laryngeal proteins and contribute to laryngeal damage [31, 32]. Furthermore, Johnston et al. [33, 34] showed that pepsin can enter cells via receptors and may be stored in vesicles or transported within the cells to other complex organelles in a non-acid environment. Pepsin is reactivated once the pH of the environment is optimal and cause cell damage. As a result, the laryngeal mucosa may develop chronic inflammation and release inflammatory factors that foster the genetic evolution of preliminary neoplasia into mature cancers [35, 36]. Samuels  demonstrated the presence of pepsin in Barrett’s esophageal mucosa and the capacity of nonacid pepsin to alter the in vitro expression of inflammation and carcinogenesis markers in esophageal cells. Johnston et al.  also proposed that the promotion of cell proliferation and migration by pepsin may be associated with altered expression of tumor-related genes and microRNAs. Allen  used pepsin and 9,10-dimethyl-1,2-benzanthracene (DMBA) to stimulate the tumors of hamster cheek pouch and observed that tumor volume was significantly higher in the presence of pepsin than without pepsin; hence pepsin might be a potential cofactor required for tumor growth. Our recent study  indicated that patients with laryngeal carcinoma have the highest expression levels of pepsin, followed by patients with vocal cord leukoplakia and control subjects. Thus, pepsin may be associated with laryngeal cancer and might contribute to the development of laryngopharyngeal carcinogenesis. Further studies are required to elucidate the precise role of pepsin and the mechanism involved.
As the mean pH of the laryngopharynx is 6.8 [39, 40], the Hep-2 and Tu212 cells in the current study were exposed to pepsin at pH 7 and the proliferation and migration of the cells were assessed. Results from the current study provided strong evidence that pepsin promoted the proliferation and migration of Hep-2 and Tu212 cells in vitro. This suggests that pepsin functions as a tumor-promoting factor in laryngeal carcinoma. This is consistent with the results from correlation studies [22, 41, 42].
The Hep-2 and Tu212 cells transformed from typical polygons to fibroblast-like long spindles under pepsin stimulation, which was reminiscent of EMT. Thus, we hypothesized that pepsin stimulation might induce EMT of tumor cells and further promote tumor metastasis. Although Lorenz and colleagues  did not study laryngeal carcinoma, they proposed a correlation between EMT and reflux for the first time. In that study, the severity of reflux correlated with EMT scores, while the EMT grades of patients with expanded fistula were significantly higher than those without fistula expansion. Furthermore, Shellman et al.  showed that bile acids contribute to pharyngeal carcinogenesis via EMT. Several other studies have shown that repeated gastric acid and pepsin exposure stimulates the laryngeal epithelium mucosa to change the E-cadherin/β-catenin complex, which may be a potential risk factor for the development of laryngeal neoplasms [43,44,45,46,47].
To test our hypothesis that reflux of pepsin into the laryngopharynx can induce EMT in laryngeal carcinoma, we evaluated the expression of EMT markers in pepsin-stimulated Hep-2 and Tu212 cells. Our results showed that pepsin exposure reduced the expression of the epithelial marker E-cadherin and increased the expression of the mesenchymal markers vimentin and β-catenin, which was similar to the results observed with immunohistochemistry of laryngeal cancer tissue. Meanwhile, expression of the EMT transcription factors snail and slug correlated with pepsin concentration. Thus, we speculated that pepsin may change the expression of snail and slug via signaling pathways, inhibit E-cadherin expression, hinder adhesion of epithelial cells, and weaken the ability of cells to maintain their shapes . Defect in E-cadherin expression may result in the release of β-catenin from the cell membrane and its accumulation in the cytoplasm, thereby connecting laryngeal mucosa epithelial cell damage with increase in epithelial permeability [49, 50]. The increase in vimentin protein expression improved cellular flexibility, mobility, and anti-immune capability , which induced EMT in laryngeal carcinoma.
Previous studies have proposed that inflammatory cytokines, such as transforming growth factor and interleukin, play crucial roles in EMT induction [52,53,54]. We analyzed cytokine concentrations in serum exposed to pepsin using CBA assays and observed a significant increase in IL-8 levels, which was dependent on the dose of pepsin. In addition, pepsin and IL-8 expression correlated positively in laryngeal carcinoma tissue. These observations are consistent with the results of Samuels et al. . Furthermore, pepstatin is well known to be an inhibitor of aspartic proteinases such as pepsin, cathepsins D and E . Kim observed that pepsin from extraesophageal reflux aggravates tonsil hypertrophy and pepstatin exerts a protective effect by inhibiting pepsin activity . Our results showed that IL-8 level was reduced when pepsin was inhibited by pepstatin; this coincided with significant upregulation of epithelial markers and downregulation of mesenchymal markers.
IL-8 is a multifunctional cytokine that participates in acute inflammation and as an extracellular signaling factor in the tumor microenvironment. Fernando et al.  demonstrated that IL-8 secreted by the human head and neck squamous cell carcinoma (HNSCC) cells undergoing EMT may play a crucial role in promoting tumor progression of HNSCC. To clarify whether IL-8 had a causal relationship with pepsin and EMT in Hep-2 and Tu212 cells, we suppressed CXCR2 using SB225002  to inhibit the binding of IL-8 to CXCR2 during pepsin treatment. Cancer cells express the CXC receptors CXCR 1 and 2, and IL-8, the ligand for these receptors, stimulates migration and proliferation of these tumor cells . We suppressed CXCR2 during pepsin treatment and observed that the pepsin-mediated promotion of cell proliferation and migration was inhibited. Blocking of CXCR2 expression during pepsin treatment partially restored the downregulation of epithelial markers and the upregulation of mesenchymal markers and transcription factors of EMT in Hep-2 and Tu212 cells. However, suppressed CXCR2 did not completely inhibit phenotype caused by pepsin, indicating either insufficient inhibition of IL8 or other inflammatory factors to play a role beside IL-8. Reflux causes epithelial cells to secrete chemokines, including IL-8, which leads to mucosal damage through inflammatory cell recruitment . The inflammatory cells and cytokines found in tumors are more likely to contribute to tumor growth and progression, and deletion or inhibition of inflammatory cytokines inhibits the development of experimental cancer [36, 58]. Additionally, inflammatory cells can release chemicals, notably reactive oxygen species, that are actively mutagenic for nearby cancer cells, accelerating their genetic evolution toward states of heightened malignancy . Studies demonstrated that pepsin induced the secretion of IL-8, which promoted EMT of laryngeal cancer (Fig. 5). EMT may reduce the protective ability of the cell epithelium by changing E-cadherin/β-catenin [48, 49], thereby destroying the histological barrier of the region invaded by tumor cells, facilitating cell separation and shedding, and finally contributing to cell migration and metastasis . Inhibition of IL-8 binding to CXCR2 partially restored the effect of pepsin on laryngeal cancer cells.
We propose that pepsin induced EMT in laryngeal carcinoma and provided new evidence for the role of LPR in laryngeal cancer tumorigenesis. LPR-associated pepsin may stimulate tumor cells to secrete IL-8 and activate the transcription factor snail to promote EMT in laryngeal cancer. Pepsin-induced EMT of laryngeal carcinoma provides a theoretical basis for understanding the pathogenesis of LPR in laryngeal carcinoma progression.
human laryngeal carcinoma cell line
human laryngeal carcinoma cell line
Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and Pepsin in the development of laryngeal injury. Laryngoscope. 1991;101:1–78.
Hawkshaw MJ, Pebdani P, Sataloff RT. Reflux laryngitis: an update, 2009–2012. J Voice. 2013;27:486–94.
Beltsis A, Katsinelos P, Kountouras J, Kamarianis N, Zavos C, Pournaras A, et al. Double probe pH-monitoring findings in patients with benign lesions of the true vocal folds: comparison with typical GERD and the effect of smoking. Eur Arch Otorhinolaryngol. 2011;268:1169–74.
Chu EA, Kim YJ. Cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am. 2008;41:673–95.
Shangina O, Brennan P, Szeszenia-Dabrowska N, Mates D, Fabiánová E, Fletcher T, et al. Occupational exposure and laryngeal and hypopharyngeal cancer risk in central and eastern Europe. Am J Epidemiol. 2006;164:367–75.
Hashibe M, Boffetta P, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, et al. Contribution of tobacco and alcohol to the high rates of squamous cell carcinoma of the supraglottis and glottis in Central Europe. Am J Epidemiol. 2007;165:814–20.
Sereg-Bahar M, Jerin A, Hocevar-Boltezar I. Higher levels of total pepsin and bile acids in the saliva as a possible risk factor for early laryngeal cancer. Radiol Oncol. 2015;49:59–64.
Langevin SM, Michaud DS, Marsit CJ, Nelson HH, Birnbaum AE, Eliot M, et al. Gastric reflux is an independent risk factor for laryngopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2013;22:1061–8.
Qadeer MA, Lopez R, Wood BG, Esclamado R, Strome M, Vaezi MF. Does acid suppressive therapy reduce the risk of laryngeal cancer recurrence? Laryngoscope. 2005;115:1877–81.
Ozlugedik S, Yorulmaz I, Gokcan K. Is laryngopharyngeal reflux an important risk factor in the development of laryngeal carcinoma? Eur Arch Otorhinolaryngol. 2006;263:339–43.
Coca-Pelaz A, Rodrigo JP, Takes RP, Silver CE, Paccagnella D, Rinaldo A, et al. Relationship between reflux and laryngeal cancer. Head Neck. 2013;35:1814–8.
Koufman JA, Aviv JE, Casiano RR, Saw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg. 2002;127:32–5.
Abou-Ismail A, Vaezi MF. Evaluation of patients with suspected laryngopharyngeal reflux: a practical approach. Curr Gastroenterol Rep. 2011;13:213–8.
Li X, Huang Z, Wu T, Wang L, Wu J. Role of laryngopharyngeal reflux on the pathogenesis of vocal cord leukoplakia and early glottic cancer. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;49:362–7.
Farhath S, He Z, Nakhla T, Saslow J, Soundar S, Camacho J, et al. Pepsin, a marker of gastric contents, is increased in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatrics. 2008;121:e253–9.
Stovold R, Forrest IA, Corris PA, Murphy DM, Smith JA, Decalmer S, et al. Pepsin, a biomarker of gastric aspiration in lung allografts: a putative association with rejection. Am J Respir Crit Care Med. 2007;175:1298–303.
Crapko M, Kerschner JE, Syring M, Johnston N. Role of extra-esophageal reflux in chronic otitis media with effusion. Laryngoscope. 2007;117:1419–23.
Knight J, Lively MO, Johnston N, Dettmar PW, Koufman JA. Sensitive pepsin immunoassay for detection of laryngopharyngeal reflux. Laryngoscope. 2005;115:1473–8.
Samuels TL, Johnston N. Pepsin as a marker of extraesophageal reflux. Ann Otol Rhinol Laryngol. 2010;119:203–8.
Wang L, Liu X, Liu YL, Zeng FF, Wu T, Yang CL, et al. Correlation of pepsin-measured laryngopharyngeal reflux disease with symptoms and signs. Otolaryngol Head Neck Surg. 2010;143:765–71.
Johnston N, Yan JC, Hoekzema CR, Samuels TL, Stoner GD, Blumin JH, et al. Pepsin promotes proliferation of laryngeal and pharyngeal epithelial cells. Laryngoscope. 2012;122:1317.
Kelly EA, Samuels TL, Johnston N. Chronic pepsin exposure promotes anchorage-independent growth and migration of a hypopharyngeal squamous cell line. Otolaryngol Head Neck Surg. 2014;150:618–24.
Lorenz KJ, Kraft K, Graf F, Pröpper C, Steinestel K. Role of reflux-induced epithelial–mesenchymal transition in periprosthetic leakage after prosthetic voice rehabilitation. Head Neck. 2014;37:530–6.
Shellman Z, Aldhahrani A, Verdon B, Mather M, Paleri V, Wilson J, et al. Bile acids: a potential role in the pathogenesis of pharyngeal malignancy. Clin Otolaryngol. 2017;42:969–73.
Tan JJ, Wang L, Huang ZF, Li YF, Tian WD, Liu X, et al. The expression and significance of pepsin in laryngeal carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016;51:593–9.
Samuels TL, Johnston N. Pepsin as a causal agent of inflammation during nonacidic reflux. Otolaryngol Head Neck Surg. 2009;141:559–63.
Bulmer DM, Ali MS, Brownlee IA, Dettmar PW, Pearson JP. Laryngeal mucosa: its susceptibility to damage by acid and pepsin. Laryngoscope. 2010;120:777–82.
Tsai TL, Chang SY, Ho CY, Kou YR. Role of ATP in the ROS-mediated laryngeal airway hyperreactivity induced by laryngeal acid-pepsin insult in anesthetized rats. J Appl Physiol. 1985;2009(106):1584–92.
Sillem M, Hahn U, Coddington CC, Gordon K, Runnebaum B, Hodgen GD. Ectopic growth of endometrium depends on its structural integrity and proteolytic activity in the cynomolgus monkey(Macaca fascicularis) model of endometriosis. Fertil Steril. 1998;66:468–73.
Goda AE, Koyama M, Sowa Y. Molecular mechanisms of the antitumor activity of SB225002: a novel microtubule inhibitor. Biochem Pharmacol. 2013;85:1741–52.
Johnston N, Knight J, Dettmar PW, Lively MO, Koufman J. Pepsin and carbonic anhydrase isoenzyme III as diagnostic markers for laryngopharyngeal reflux disease. Laryngoscope. 2004;114:2129–34.
Johnston N, Dettmar PW, Lively MO, et al. Effect of Pepsin on laryngeal stress protein (Sep70, Sep53, and Hsp70) response: role in laryngopharyngeal reflux disease. Ann Otol Rhinol Laryngol. 2006;115:47–58.
Johnston N, Wells CW, Blumin JH, Toohill RJ, Merati AL. Receptor-mediated uptake of pepsin by laryngeal epithelial cells. Ann Otol Rhinol Laryngol. 2007;116:934–8.
Johnston N, Wells CW, Samuels TL, Blumin JH. Rationale for targeting pepsin in the treatment of reflux disease. Ann Otol Rhinol Laryngol. 2010;119:547–58.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Samuels T, Hoekzema C, Gould J, Goldblatt M, Frelich M, Bosler M, et al. Local synthesis of pepsin in Barrett’s esophagus and the role of pepsin in esophageal adenocarcinoma. Ann Otol Rhinol Laryngol. 2015;124:893–902.
Adams J, Heintz P, Gross N, Andersen P, Everts E, Wax M, et al. Acid/pepsin promotion of carcinogenesis in the hamster cheek pouch. Arch Otolaryngol Head Neck Surg. 2000;126:405–9.
Wood JM, Hussey DJ, Woods CM, Watson DI, Carney AS. Biomarkers and laryngopharyngeal reflux. J Laryngol Otol. 2011;125:1218–24.
Wood J, Hussey DJ, Woods CM, et al. Does gene expression in laryngeal sub-sites differ between patients with laryngopharyngeal reflux and controls? Clin Otolaryngol. 2018;43:158–63.
Johnston N, Wells CW, Samuels TL, Blumin JH. Pepsin in nonacidic refluxate can damage hypopharyngeal epithelial cells. Ann Otol Rhinol Laryngol. 2009;118:677–85.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63:11–30.
Johnston N, Bulmer D, Gill GA, Panetti M, Ross PE, Pearson JP, et al. Cell biology of laryngeal epithelial defenses in health and disease: further studies. Ann Otol Rhinol Laryngol. 2003;112:481–91.
Reichel O, Mayr D, Durst F, Berghaus A. E-cadherin but not beta-catenin expression is decreased in laryngeal biopsies from patients with laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2008;265:937–42.
Galera-Ruiz H, Ríos-Moreno MJ, González-Cámpora R, Ortega I, Fernández A, García-Escudero A, et al. The cadherin-catenin complex in laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2011;269:1183–8.
Lehembre F, Yilmaz M, Wicki A, Schomber T, Strittmatter K, Ziegler D, et al. NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J. 2008;27:2603–15.
Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, Lambin P, et al. E-cadherin loss associated with EMT promotes radio resistance in human tumor cells. Radiother Oncol. 2011;99:392–7.
Yan B, Zhang W, Jiang LY, Qin WX, Wang X. Reduced E-cadherin expression is a prognostic biomarker of non-small cell lung cancer: a metaanalysis based on 2395 subjects. Int J Clin Exp Med. 2014;7:4352–6.
Pecina Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003;3:17.
Fuxe J, Karlsson MC. TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol. 2012;22:455–61.
Satelli A, Li S. Vimemin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033–46.
Cianfrocca R, Tocci P, Spinella F, Di Castro V, Bagnato A, Rosanò L. The endothelin A receptor and epidermal growth factor receptor signaling converge on b-catenin to promote ovarian cancer metastasis. Life Sci. 2012;91:13–4.
Mikami Y, Yamauchi Y, Horie M, Kase M, Jo T, Takizawa H, et al. Tumor necrosis factor superfamily member LIGHT induces epithelial–mesenchymal transition in A549 human alveolar epithelial cells. Biochem Biophys Res Commun. 2012;428:451–7.
Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, et al. Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009;28:2940–7.
Umezawa H, Aoyagi T, Morishima H, Matsuzaki M, Hamada M. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo). 1970;23:259–62.
Kim JH, Jang SJ, Yun JW, Jung MH, Woo SH. Effects of pepsin and pepstatin on reflux tonsil hypertrophy in vitro. PLoS ONE. 2018;13:e0207090.
Chan LP, Liu C, Chiang FY, Wang LF, Lee KW, Chen WT. IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCC. Oncotarget. 2017;8:56375–88.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.
Souza RF, Huo X, Mittal V, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanismrather than caustic acid injury. Gastroenterology. 2009;137(5):1776–84.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.
J-JT, LW, and X-PL designed the study, wrote the article, analyzed the data, and approved the final manuscript, and are accountable for all aspects of the work. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
Consent for publication
Ethics approval and consent to participate
This study was performed in accordance with institutional ethical guidelines and was approved by the Ethics Committee of Nanfang Hospital. Informed written consent was obtained from each patient.
This study was supported by The National Natural Science Foundation of China (No. 81400452).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Tan, J., Wang, L., Mo, T. et al. Pepsin promotes IL-8 signaling-induced epithelial–mesenchymal transition in laryngeal carcinoma. Cancer Cell Int 19, 64 (2019) doi:10.1186/s12935-019-0772-7
- Laryngopharyngeal reflux
- Laryngeal carcinoma